

A

Docket # PF-0148-2 DIV



36
10/8/99



"Express Mail" mailing label number EL315813786 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissioner for Patents, Box PATENT APPLICATION, Washington, D.C. 20231 on October 8, 1999

By: Nancy Ramos

Printed: Nancy Ramos

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
REQUEST FOR FILING A PATENT APPLICATION UNDER 37 CFR 1.53(b)**

Assistant Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Dear Sir:

This is a request for filing a **DIVISIONAL** application under 37 CFR 1.53(b) of pending prior application Serial No.09/134,593, filed on August 13, 1998, entitled NOVEL HUMAN PYROPHOSPHATASE, which is a divisional of issued patent no. 5,843,665, Serial No.08/741,437, filed on October 31, 1996, entitled HUMAN PYROPHOSPHATASE.

1. ☒ Enclosed is a copy of the prior application, U. S. Application Serial No.08/741,437 filed October 31, 1996, including the oath or declaration as originally signed.
2. ☒ With regard to the requirement of 37 CFR 1.821(e) which requires that a copy of the Sequence Listing in computer readable form (CRF) be submitted, Applicants state that the computer readable form of the "Sequence Listing" for the instant divisional application is identical with that filed for Serial No. 08/741,437, filed October 31, 1996, to which priority is claimed. In accordance with 37 C.F.R. §1.821(e), please use the computer readable form filed with U.S. Application Serial No. 08/741,437 as the computer readable form for the instant divisional application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant divisional application.
3. ☒ Cancel in this application original claims 2-16 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
4. ☒ The inventor(s) of the invention being claimed in this application is (are): Phillip R. Hawkins and Jennifer L. Hillman.

5. X In accordance with 37 CFR 1.63(d) a copy of the originally signed declaration showing applicant's/applicants' signature(s) as filed on January 6, 1997 is enclosed.

6. X Amend the specification by inserting before the first line the sentence: "This application is a divisional application of U.S. application serial number 08/741,437, filed October 31, 1996, which is a divisional of U.S. patent no. 5,843,665, U.S. serial no. 09/134,593, filed August 13, 1998."

7. X The filing fee is calculated below:

Claims	Number Filed	Minus	Number Extra	Other Than Small Entity Rate	Basic Fee
					\$760.00
Total Claims	3	-20	0	x \$18	\$0
Indep. Claims	1	-3	0	x \$78	\$0
Multiple Dependent Claim(s), if any + \$260					\$0

TOTAL FILING FEE \$ 0

8. ___ An extension of time in the above-named prior application has been requested and the fees therefore have been authorized in said application.
9. X Please charge Incyte Pharmaceuticals, Inc. Deposit Account No. 09-0108 in the amount of \$ 760.00
The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Incyte Pharmaceuticals, Inc. Account No. 09-0108.

Duplicate copies of these papers are enclosed.

10. X New formal drawings are enclosed.
11. X The prior application is assigned of record to Incyte Pharmaceuticals, Inc., recorded on January 16, 1997, at reel 8437, frame 0115.
12. X A preliminary amendment is enclosed.
13. X Also enclosed Information Disclosure Statement (2 pp., in duplicate); and List of References Cited PTO-1449 (1 p.); copy of previously submitted Revocation and Power of Attorney (2 pp.).

14. X The power of attorney of the prior application is to:

Narinder S. Banait	Reg. No. 43,482
Adam Warwick Bell	Reg. No. 43,490
Lucy J. Billings	Reg. No. 36,749
Michael C. Cerrone	Reg. No. 39,132
Diana Hamlet-Cox	Reg. No. 33,302
Colette C. Muenzen	Reg. No. 39,784
Lynn E. Murry	Reg. No. 42,918
Danielle M. Pasqualone	Reg. No. 43,847
Susan K. Sather	Reg. No. 44,316
David G. Streeter	Reg. No. 43,168

- a. An associate power of attorney is attached.
- b. Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c. X Address all future correspondence to:

INCYTE PHARMACEUTICALS, INC.
PATENT DEPARTMENT
3174 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555, Fax: (650) 849-8886

Date:

18 October 1999

By:



Diana Hamlet-Cox, Ph.D.

Reg. No. 33,302

Direct Dial Telephone: (650) 845-4639

- Inventor(s)
- Assignee of complete interest
- X Attorney or agent of record
- Filed under 37 CFR 1.34(a)
- Registration number if acting under 37 CFR 1.34(a)

"Express Mail" mailing label number EL315813786 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissioner for Patents, Box PATENT APPLICATION, Washington, D.C. 20231 on October 8, 1999

By: Nancy RamosPrinted: Nancy Ramos

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hawkins et al.

Title: A NOVEL HUMAN PYROPHOSPHATASE

Serial No.: To Be Assigned

Filing Date:

Herewith

Examiner: To Be Assigned

Group Art Unit:

To Be Assigned

Official Draftsman

Assistant Commissioner for Patents
Washington, D.C. 20231

SUBMISSION OF FORMAL DRAWINGS

Sir:

Transmitted herewith are Figure(s) 1A, 1B, 1C, 1D, 2A, 2B, 3, 4, and 5, as nine (9) sheets of formal drawings for this application. Each sheet of drawing indicates the identifying indicia suggested in 37 CFR Section 1.84(c) on the reverse side of the drawings. Applicants note that the number of sheets of drawings has increased to accomodate the Draftspersons objections. The new formal drawings are identical to those originally filed. No new matter has been added.


Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Incyte Pharmaceuticals, Inc. Deposit Account No. **09-0108**. **A duplicate copy of this communication is enclosed.**

If there are any questions regarding the above, the Examiner is invited to call the undersigned.

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

Date: 08 October 1999



Diana Hamlet-Cox, Ph.D.

Reg. No. 33,302

Direct Dial Telephone: (650) 845-4639

3174 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

668001-0451460